[HTML][HTML] Host-targeted antivirals against SARS-CoV-2 in clinical development-prospect or disappointment?

A Schreiber, S Ludwig - Antiviral Research, 2025 - Elsevier
The global response to the COVID-19 pandemic, caused by the novel SARS-CoV-2 virus,
has seen an unprecedented surge in the development of antiviral therapies. Traditional …

Hydroxychloroquine and COVID-19 story: is the low-dose treatment the missing link? A comprehensive review and meta-analysis

I Ramdani, B Bouazza - Naunyn-Schmiedeberg's Archives of …, 2024 - Springer
Hydroxychloroquine (HCQ) has been repurposed and used for the treatment of COVID-19
patients; however, its efficacy remains controversial, maybe partly due to the dosage …

Loop-mediated isothermal nucleic acid amplification coupled with CRISPR-Cas12b for rapid and sensitive detection of SARS-CoV-2 and Nipah virus

DMS Kielich - 2023 - mspace.lib.umanitoba.ca
SARS-CoV-2 and Nipah virus are two zoonotic viruses responsible for global and local
outbreaks of high consequence, respectively, putting a strain on capacity for rapid testing …